Logo

ANEB

Anebulo Pharmaceuticals, Inc.

ANEB

Anebulo Pharmaceuticals, Inc. • NASDAQ
$2.27 ▼ -2.99% (-0.07)
Market Cap $93.26 M
52w High $3.42
52w Low $0.80
Dividend Yield 0%
P/E -10.32
Volume 2.60K
Outstanding Shares 41.08M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 $2.26M ▼ $-2.158M ▼ 0% $-0.05 ▲ $-2.141M ▼
Q4-2025 $0 $2.331M ▲ $-2.145M ▼ 0% $-0.052 ▼ $-2.127M ▼
Q3-2025 $0 $1.892M ▼ $-1.676M ▲ 0% $-0.041 ▲ $-1.431M ▲
Q2-2025 $0 $2.588M ▲ $-2.463M ▼ 0% $-0.09 ▼ $-2.403M ▼
Q1-2025 $0 $2.412M $-2.201M 0% $-0.085 $-1.87M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $10.355M ▼ $10.701M ▼ $963.821K ▲ $9.737M ▼
Q4-2025 $11.628M ▼ $12.146M ▼ $487.688K ▼ $11.658M ▼
Q3-2025 $13.28M ▼ $14.008M ▼ $546.032K ▼ $13.462M ▼
Q2-2025 $14.998M ▲ $15.841M ▲ $878.799K ▲ $14.962M ▲
Q1-2025 $1.404M $2.468M $569.225K $1.899M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-2.158M ▼ $-1.273M ▲ $0 $0 $-1.273M ▲ $-1.273M ▲
Q4-2025 $-2.145M ▼ $-1.652M ▼ $0 $0 ▲ $-1.652M ▲ $-1.652M ▼
Q3-2025 $-1.676M ▲ $-1.602M ▼ $0 $-116.664K ▼ $-1.719M ▼ $-1.602M ▼
Q2-2025 $-2.463M ▼ $-1.406M ▲ $0 $15M ▲ $13.594M ▲ $-1.406M ▲
Q1-2025 $-2.201M $-1.69M $0 $0 $-1.69M $-1.69M

Five-Year Company Overview

Income Statement

Income Statement Anebulo is still a pure development-stage biotech: it has no product revenue yet and its costs are mainly research, clinical work, and overhead. Losses have been steady over the past several years, reflecting ongoing spending to advance its lead drug rather than any operational scale. Per-share losses were larger in the early years after IPO and have become somewhat smaller more recently, but the business model is still firmly in the “spend to develop, not yet earning” phase. Profitability will depend entirely on whether its pipeline successfully reaches market and gains adoption.

Balance Sheet

Balance Sheet The balance sheet is simple and typical for a small clinical-stage biotech. Assets are mostly cash and equivalents, with very little in the way of physical assets or inventory. There is effectively no debt, so financial leverage risk is low, but the equity base and overall asset level are modest, which limits the company’s cushion if development takes longer or becomes more expensive than expected. Future progress will likely require additional external funding unless partnered deals or milestone payments emerge.

Cash Flow

Cash Flow Cash flow reflects a company that is investing rather than earning: operating cash flow is consistently negative, and free cash flow mirrors this since capital spending is minimal. In other words, nearly all cash use is going into operating activities such as R&D and clinical trials, not facilities or equipment. Sustainability of this cash burn hinges on access to new capital or partnerships; absent revenue, the company’s runway is tied to its cash balance and financing options.

Competitive Edge

Competitive Edge Anebulo’s competitive position is built around being an early mover in a very specific niche: treating acute cannabis intoxication. There are currently no approved drugs targeted at this condition, so the company is trying to define a new standard of care rather than displace existing therapies. Its moat rests on first-mover status, patent protection around its lead compound, and the growing medical need as cannabis use and related emergency visits increase. However, as a small company focused on a single main asset, it remains vulnerable to larger entrants, changing clinical views, and any negative trial or regulatory outcomes.

Innovation and R&D

Innovation and R&D Innovation is the core of Anebulo’s story. The lead drug, selonabant, is designed to directly block the brain receptor that THC activates, aiming to quickly reverse cannabis intoxication. The company is pursuing both oral and intravenous forms, which could suit different use cases—from less urgent cases to emergency-room settings, including pediatric incidents. Clinical data so far are early-stage but supportive enough to justify continued development. The key uncertainties are the usual ones for biotech: whether later-stage trials confirm safety and efficacy, how regulators view the unmet need, and how quickly providers might adopt a new treatment if approved.

Summary

Anebulo is a very early, high-risk, high-uncertainty biotech focused on a single, differentiated idea: a drug to rapidly treat cannabis overdose and intoxication. Financially, it is pre-revenue, runs steady losses, relies on its cash balance and future financing, and carries no meaningful debt. Strategically, it holds a first-mover position in a growing problem area, supported by patents and a focused R&D effort. The company’s future value is tightly linked to the clinical, regulatory, and commercial success of selonabant; until there is clearer visibility on these milestones, its profile remains that of a small, development-stage biotech with significant upside potential but substantial execution and funding risk.

NEWS

November 13, 2025 · 4:05 PM UTC

Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates

Read more

September 29, 2025 · 4:05 PM UTC

Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates

Read more

September 25, 2025 · 7:30 AM UTC

Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity

Read more